CPhI Worldwide announces the winners of the 16th Pharma Awards

CPhI Worldwide 2019 5 - 7 November 2019, Frankfurt, Germany.
CPhI Worldwide, organised by Informa PLC, announced the winners of the prestigious 2019 CPhI Pharma Awards - celebrating the industry's top innovators, performers and outstanding achievements across 13 categories, spanning the entire industry supply chain. The winners have been recognised for delivering excellence in pharma and were unveiled during a ceremony on the opening evening of CPhI Worldwide in Frankfurt.

The prestigious 'CEO of the Year' award has been bestowed upon Dr. Ge Li, Founder, Chairman and CEO of WuXi AppTec who was chosen for his significant contribution to the global biopharma R&D industry. Under his leadership, WuXi AppTec has become a highly respected contributor to global healthcare innovation. The company is enabling more than 3,700 customers and partners in more than 30 countries by offering open-access capabilities and services, accelerating the discovery and development of new medicines for patients around the world.

For the second time in three years, Cambrex was awarded the ‘API Development’ category for their Crystallisation Screening and Process Development Service. The service has bridged the gap between the bench and manufacturing plat, providing controlled, robust and scalable crystallization processes. Hovione received a ‘highly commended’ acknowledgement for their Process Ranking of Inputs from Manufacturing (PRIME).

John Chiminski, Chair and CEO at Catalent Pharma Solutions, won the ‘Lifetime Achievement’ award for his accomplishments spanning more than three decades. These include the last 10 years at Catalent, during which time the company has become a true benchmark of advanced delivery technologies, development, and manufacturing solutions.

The 'Formulation' award was given to Nanoform for its controlled expansion of supercritical solutions (CESS®). Spraying Systems Co. / Fluid Air Inc. were bestowed with the 'Manufacturing Technology and Equipment' award for their PolarDry®' - the Cooler Technology. Cited as the future of spray drying, it utilises electrostatic technology to prevent against API loss, degradation, and denaturalisation.

Univercells received the ‘Bioprocessing and Manufacturing’ award in recognition of its NevoLine PlatformTM, which is a bioproduction system for vaccines. The ‘Regulatory Procedures and Compliance' prize was given to Merck Healthcare KGaA for ‘Project SARA’ (Smart Assistant for Regulatory Affairs).

The 'Analysis, Testing, and Quality Control' category was claimed by MedPharm for pioneering the regulatory approval of topical products using in vitro bioequivalence. MedPharm is the first contract research organisation to gain regulatory approval using in vitro models to demonstrate the bioequivalence of a generic formulation compared to the originator.

SCHOTT Pharmaceutical Systems and W.L. Gore & Associates received the ‘Packaging’ award for its syriQ BioPure® - a silicone-free syringe - whilst Hoffmann Neopac was highly commended for their STYLO Spatula applicator.

The winner of the ‘Pharma Service Company of the Year Award’ is Lonza Pharma & Biotech. The company is recognised for its integrated global services offering that spans the pharmaceutical, biotech, consumer health and specialty chemicals market.

In 'Contract Services and Outsourcing' Nanopharm Ltd - an Aptar pharma company - was selected as the winner for SmartTrack™, with CMAC being highly commended for their CMAC National Facility. Finally, the award for 'Drug Delivery and Devices' was given to Phillips-Medisize for its Connected Health Platform, and the 'Supply Chain, Logistics and Distribution' category was given to Kemiex AG.

Tara Dougal, Head of Content at Informa, commented: "The judges noted that this year our entries possessed an extremely high standard. All of the finalists would have would have made outstanding winners in previous years. On behalf of CPhI Worldwide, I would like to extend my congratulations to all the winners and commend all of the finalists. What you are doing is of tremendous benefit to the industry, but more importantly, it is also directly contributing to improved patient experiences globally."

For more information on the CPhI Pharma Awards please visit: http://awards.cphi.com

The 2019 CPhI Pharma Award winner by category

  • Excellence in Pharma: Analysis, Testing, and Quality Control - MedPharm regulatory approval of topical products using in vitro bioequivalence
  • Excellence in Pharma: API Development - Cambrex crystallisation screening and process development service. Highly commended - Hovione process ranking of inputs from manufacturing
  • Excellence in Pharma: Bioprocessing & Manufacturing - Univercells The NevoLine PlatformTM
  • Excellence in Pharma: Contact Services and Outsourcing - Nanopharm Ltd, an Aptar Pharma Company Smart Track. Highly commended - CMAC, CMAC National Facility
  • Excellence in Pharma: Formulation - Nanoform Controlled Expansion of Supercritical Solutions
  • Excellence in Pharma: Manufacturing Technology and Equipment - Spraying Systems Co./Fluid Air Inc PolarDry The Cooler Technology
  • Excellence in Pharma: Drug Delivery Devices - Phillips-Medisize Connected Health Platform
  • Excellence in Pharma: Packaging - SCHOTT Pharmaceutical Systems and W.L Gore & Associates syriQ BioPure silicone-free syringes with GORE ImproJect Plungers. Highly commended - Hoffman Neopac STYLO Spatula applicator for Canseten footcare Cream Bayer Consumer Health
  • Excellence in Pharma: Regulatory Procedures and Compliance - Merck Healthcare KGaA Project SARA (Smart Assistant for Regulatory Affairs)
  • Excellence in Pharma: Supply Chain Logistics and Distribution - Kemlex AG Trade Network for Life Sciences Raw Materials
  • CEO of the Year: Dr. Ge Li, Founder, Chairman & CEO, WuXi AppTec
  • Pharma Service Company of the Year: Lonza Pharma & Biotech
  • Lifetime Achievement Award: John Chiminski, Chair and CEO at Catalent Pharma Solutions

About CPhI

CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, Korea, China, India, Japan, South East Asia, North America, and the Middle East and Africa. Co-locating with ICSE for contract services; P-MEC for machinery, equipment & technology; InnoPack for pharmaceutical packaging; bioLIVE for biopharma; and Finished Dosage Formulation for every aspect of the finished dosage supply chain.

About Informa Markets

Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organiser, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year.

The Informa Markets annual schedule of Pharmaceutical events include: CPhI, ICSE, P-MEC, FDF, InnoPack Worldwide, BioProduction (5-7, November, 2019 at the Messe in Frankfurt); CPhI & P-MEC India (26 - 28 November 2019 at the India Expo Mart, Greater Noida, Delhi NCR - Delhi, India); Pharmapack Europe (5 - 6 February, 2020 at the Paris Expo, Porte de Versailles - Paris, France); CPhI South East Asia (4 - 6 March, 2020 at the QSNCC - Bangkok, Thailand); CPhI Japan (16 - 18 March, 2020 at the Big Sight Exhibition Centre - Tokyo, Japan); CPhI North America (05 April - 07 May, 2020 at Pennsylvania Convention Centre - Philadelphia, USA); CPhI and P-MEC China (22 - 24 June, 2020 at SNIEC - Shanghai, China); CPhI Korea (26 - 28 August 2020), COEX - Seoul, Korea); CPhI Middle East & Africa (14 - 16 September, 2020 at the ADNEC - Abu Dhabi, United Arab Emirates)

Most Popular Now

Theravance Biopharma and Pfizer Inc. enter global …

Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Pfizer Inc. (NYSE: PFE) ("Pfizer") today anno...

Amgen and Allergan submit Biologics License Applic…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) fo...

Researchers identify immune-suppressing target in …

Researchers at The University of Texas MD Anderson Cancer Center have identified a tenacious subset of immune macrophages that thwart treatment of glioblastoma with anti-...

Intermittent fasting: live 'fast,' live longer?

For many people, the New Year is a time to adopt new habits as a renewed commitment to personal health. Newly enthusiastic fitness buffs pack into gyms and grocery stores...

Pharmacies leave customers hanging when it comes t…

Proper disposal of leftover medication, particularly antibiotics and opioids, can help reduce antibiotic resistance, prevent children from being poisoned and stop the mis...

Researchers determine how a specific protein regul…

Immune checkpoints are surface proteins that cancer cells use to evade immune response. These surface proteins are critical for cancer cell growth and drugs targeting the...

Lynparza approved in the US as a 1st-line maintena…

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that Lynparza (olaparib) has been approved in the US f...

Scientists find a new use for already known anti-c…

The world scientific community is waging a difficult and prolonged war on cancer. New research in the field of immunogenic cell death can extend the area of drugs applica...

Farxiga granted FDA Priority Review for patients w…

AstraZeneca today announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Farxiga (dap...

Lilly opens Phase 3 clinical trial in RET-mutant m…

Eli Lilly and Company (NYSE: LLY) announced the opening of the LIBRETTO-531 clinical trial [NCT04211337] for selpercatinib, also known as LOXO-292, for treatment-naive RE...

Bristol-Myers Squibb completes divestment of manuf…

Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its previously announced divestment of its oral solid, biologics, and sterile product manufa...

FDA approves new treatment option for patients wit…

Today, the U.S. Food and Drug Administration granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable (unab...